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TREATMENT WITH IRON AGENTS
BACKGROUND
Correction of iron deficiency with oral or intravenous iron
supplementation can reduce the severity of anemia in
patients with CKD.25,26 Untreated iron deficiency is an
important cause of hyporesponsiveness to ESA treatment.27,28
It is important to diagnose iron deficiency because treatment
can readily correct the associated anemia and investigation
for the cause of iron deficiency, which should follow its
detection, can lead to important diagnoses. In the absence of
menstrual bleeding, iron depletion and iron deficiency
usually result from blood loss from the gastrointestinal
tract. There are additional considerations in CKD patients
with iron deficiency. For instance, hemodialysis patients
are subject to repeated blood loss due to retention of blood in
the dialyzer and blood lines. Other contributing causes in
hemodialysis and other CKD patients include frequent
blood sampling for laboratory testing, blood loss from
surgical procedures (such as creation of vascular access),
interference with iron absorption due to medications
such as gastric acid inhibitors and phosphate binders,
and reduced iron absorption due to inflammation.29 The
reader is referred to standard textbooks of medicine and
pediatrics for more extensive discussions on the diagnosis
and evaluation of patients with known or suspected iron
deficiency.
Iron supplementation is widely used in CKD patients
to treat iron deficiency, prevent its development in ESA-
treated patients, raise Hb levels in the presence or absence
of ESA treatment, and reduce ESA doses in patients receiving
ESA treatment. Iron administration is appropriate when
bone marrow iron stores are depleted or in patients who are
likely to have a clinically meaningful erythropoietic response.
It is prudent, however to avoid iron therapy in patients
in whom it is unlikely to provide meaningful clinical
benefit, i.e., avoid transfusion and reduce anemia-related
symptoms, and in those in whom potential benefit is
outweighed by risks of treatment.23,30–32 There are relatively
few data on the long-term clinical benefits of iron
supplementation other than direct effects on the Hb
concentration. There is similarly little information on the
long-term adverse consequences of iron supplementation in
excess of that necessary to provide adequate bone marrow
iron stores.33–35 Since bone marrow aspiration for assessment
of iron stores is rarely done in clinical practice, iron
supplementation is typically assessed by blood-based iron
status tests without knowledge of bone marrow iron
stores.27,28,36–38
The following statements provide recommendations for
use of iron supplementation in patients with CKD.
2.1.1: When prescribing iron therapy, balance the
potential benefits of avoiding or minimizing
blood transfusions, ESA therapy, and anemia-
related symptoms against the risks of harm in
individual patients (e.g., anaphylactoid and other
acute reactions, unknown long-term risks). (Not
Graded)
2.1.2: For adult CKD patients with anemia not on iron or
ESA therapy we suggest a trial of IV iron (or in CKD
ND patients alternatively a 1–3 month trial of oral
iron therapy) if (2C):
K an increase in Hb concentration without start-
ing ESA treatment is desired* and
K TSAT is r30% and ferritin is r500 ng/ml
(r500 mg/l)
2.1.3: For adult CKD patients on ESA therapy who
are not receiving iron supplementation, we suggest
a trial of IV iron (or in CKD ND patients
alternatively a 1–3 month trial of oral iron therapy)
if (2C):
K an increase in Hb concentration** or a decrease
in ESA dose is desired*** and
K TSAT is r30% and ferritin is r500 ng/ml
(r500 mg/l)
2.1.4: For CKD ND patients who require iron supplemen-
tation, select the route of iron administration
based on the severity of iron deficiency, availability
of venous access, response to prior oral iron
therapy, side effects with prior oral or IV
iron therapy, patient compliance, and cost. (Not
Graded)
2.1.5: Guide subsequent iron administration in CKD
patients based on Hb responses to recent iron
therapy, as well as ongoing blood losses, iron status
tests (TSAT and ferritin), Hb concentration, ESA
responsiveness and ESA dose in ESA treated
patients, trends in each parameter, and the patient’s
clinical status. (Not Graded)
chapte r 2 http://www.kidney-international.org
& 2012 KDIGO
*Based on patient symptoms and overall clinical goals, including avoidance
of transfusion, improvement in anemia-related symptoms, and after
exclusion of active infection.
**Consistent with Recommendations #3.4.2 and 3.4.3.
***Based on patient symptoms and overall clinical goals including avoidance
of transfusion and improvement in anemia-related symptoms, and after
exclusion of active infection and other causes of ESA hyporesponsiveness.
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2.1.6: For all pediatric CKD patients with anemia not on
iron or ESA therapy, we recommend oral iron (or IV
iron in CKD HD patients) administration when
TSAT is r20% and ferritin is r100 ng/ml
(r100 lg/l). (1D)
2.1.7: For all pediatric CKD patients on ESA therapy who
are not receiving iron supplementation, we recom-
mend oral iron (or IV iron in CKD HD patients)
administration to maintain TSAT 420% and
ferritin 4100 ng/ml (4100 lg/l). (1D)
RATIONALE
In patients with CKD-associated anemia, iron supplementa-
tion is intended to assure adequate iron stores for erythro-
poiesis, correct iron deficiency, and, in patients receiving ESA
treatment, prevent iron deficiency from developing. Iron
supplementation, particularly with intravenous iron, can
enhance erythropoiesis and raise Hb levels in CKD patients
with anemia even when TSAT and ferritin levels are not
indicative of absolute iron deficiency, and even when bone
marrow studies reveal adequate iron stores.38–40 Iron
treatment, particularly when administered intravenously,
has also been consistently demonstrated to improve the
erythropoietic response to ESA treatment.27,28,32,36,37,41–43 For
any individual patient the optimal balance of Hb level, ESA
dose, and iron dose at which clinical benefit is maximized
and potential risk is minimized is not known. Prescribing
iron therapy for CKD patients is complicated by the relatively
poor diagnostic utility of serum ferritin and TSAT tests to
estimate body iron stores or for predicting a Hb response to
iron supplementation.23,30 Even examination of bone marrow
iron stores, considered the ‘gold standard’ for assessment of
iron stores, does not predict erythropoietic responsiveness to
iron supplementation in patients with CKD with a high
degree of accuracy.16,23,30,40 It is important that the short-
and long-term safety of oral and intravenous (IV) iron
agents, when known, be carefully considered when iron
therapy is prescribed, and that the potential for as yet
undiscovered toxicities also be taken into account. In each
patient there must be consideration of current and desired
Hb level, ESA dose and trends in ESA dose over time,
assessment of the Hb response to iron supplementation,
ongoing blood loss, and changes in iron status tests. While
observational studies have not for the most part produced
strong evidence of significant toxicity of chronic IV iron
administration, the clinical benefit of such treatment has also
not been convincingly demonstrated, although a recent
randomized controlled trial (RCT) in patients with heart
failure (some of whom also had mild CKD) is encouraging.44
TSAT and ferritin levels
The two most widely available tests for assessing iron status
are the TSAT and serum ferritin level. A very low serum
ferritin (o30 ng/ml [o30 mg/l]) is indicative of iron
deficiency.16 Except in this circumstance, the TSAT and
serum ferritin level have only limited sensitivity and
specificity in patients with CKD for prediction of bone
marrow iron stores and erythropoietic response to iron
supplementation16-21,40,45 (Figures 1 and 2). Their utility is
further compromised by substantial inter-patient variability
unrelated to changes in iron store status.46
Evidence to support a recommendation for specific TSAT
and ferritin levels at which iron therapy should be initiated or
as ‘targets’ for iron therapy is limited, with very few
RCTs.16–21 No iron intervention trials have been sufficiently
powered or of long enough duration to assess long-term
safety and no studies have addressed the clinical benefit, cost-
effectiveness, and risk-benefit comparison of using different
TSATand ferritin levels for the diagnosis of iron deficiency or
as a trigger for iron supplementation.
The Work Group sought to recommend iron targets that
balance diagnostic sensitivity and specificity with assump-
tions regarding safety. Previous clinical practice recommen-
dations (Kidney Diseae Outcomes Quality Initiative
[KDOQI] 2006 and others), largely opinion-based, indicated
that supplemental iron should be administered to maintain
ferritin levels4200 ng/ml (4200 mg/l) in CKD 5HD patients
and 4100 ng/ml (4100 mg/l) in CKD ND and CKD 5PD
with TSAT 420% in all CKD patients. These guidelines also
indicated that there was insufficient evidence to recommend
routine IV iron administration when the ferritin level was
4500 ng/ml (4500 mg/l).
Most CKD patients with serum ferritin levels4100 ng/ml
(4100 mg/l) have normal bone marrow iron stores,16–21 yet
many such patients will also have an increase in Hb
concentration and/or reduction in ESA dose if supplemental
iron is provided.16,23,30,31,40,45 A substantial fraction of CKD
patients with anemia and TSAT 420% respond to iron
supplementation with an increase in Hb concentration and/
Figure 1 |Receiver operating characteristic (ROC) curves,
examining the utility of iron status tests to distinguish iron
deficient from nondeficient study patients. Reprinted with
permission from Macmillan Publishers Ltd: Kidney International.
Van Wyck DB, Roppolo M, Martinez CO et al. A randomized,
controlled trial comparing IV iron sucrose to oral iron in anemic
patients with nondialysis-dependent CKD. Kidney Int 2005; 68:
2846–2856;45 accessed http://www.nature.com/ki/journal/v68/n6/
full/4495631a.html.
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or reduction in ESA dose. Therefore, for patients who have
not been receiving iron supplementation, we suggest iron
administration in anemic CKD patients with TSAT o30%
and serum ferritin o500 ng/ml (o500 mg/l) if an increase in
Hb level is desired, particularly if intended to avoid
transfusions and reduce anemia-related symptoms, and/or
reduction in ESA dose, after consideration of the potential
risks of iron administration. The safety of providing
additional iron to intentionally maintain TSAT 430% and
serum ferritin 4500 ng/ml (4500 mg/l) has been studied in
very few patients. We do not recommend routine use of iron
supplementation in patients with TSAT 430% or serum
ferritin 4500 ng/ml (4500 mg/l) since, as stated above, the
benefits and risks of doing so are inadequately studied. In all
patients receiving iron, it is important to weigh both short-
term and acute toxicities associated with iron therapy and
exclude the presence of active infection (Recommendation
2.4) before embarking on a course of IV iron treatment.
There is only very limited evidence in patients with CKD
that informs any decision about defining any specific upper
limits for iron status targets in guiding iron treatment.47,48
Previous guidelines, such as the 2006 KDOQI guidelines and
others, have specified serum ferritin levels above which
additional IV iron therapy was generally not recom-
mended,8,49–52 usually citing limits of 500–800 ng/ml
(500–800 mg/l). However, no RCTs and few other studies
have examined the efficacy and safety of providing IV iron to
maintain ferritin levels 4500–800 ng/ml (4500–800 mg/l).
Most studies are retrospective and the few prospective studies
have had small numbers of patients and short follow up,
using surrogate outcomes such as Hb and ESA dose rather
than more meaningful patient outcomes such as infection
risk and mortality. In most patients with TSAT 430% or
serum ferritin 4500 ng/ml (4500 mg/l), any erythropoietic
responsive to iron supplementation alone (i.e., the incre-
mental change in Hb and/or reduction in ESA dose) will be
small. In one RCT conducted in CKD 5HD patients with
anemia, serum ferritin 500–1200 ng/ml (500–1200 mg/l), and
TSATo25%, patients received a 25% increase in epoetin dose
and were randomly assigned to receive either no iron
(control) or 1000mg IV iron. At 6 weeks, Hb increased to
a greater extent in the IV iron group.53 This study was not
considered in the choice of target levels for ferritin and TSAT
in this guideline in part because it studied only a restricted
group of patients, all of whom also received an increase in
ESA dose. The number of patients was too small and the
period of observation too short to assess either clinically
important outcomes or toxicity in a meaningful way
(Supplementary Tables 2–4 online).
High ferritin levels in some studies have been associated
with higher death rates, but whether elevation of ferritin
levels is a marker of excessive iron administration rather than
a nonspecific acute phase reactant is not clear. At increasingly
higher ferritin levels, there is some evidence to indicate that
hepatic deposition of iron increases.54,55 Clinical sequelae of
this have not been documented although such hepatic iron
deposition might be of particular concern in patients with
hepatitis C virus (HCV) infection.56 While some data are
available linking ferritin levels in patients with hemochro-
matosis and transfusional tissue iron deposition in patients
without CKD,57 it is not clear to what extent these findings
are relevant to CKD patients or should be used to guide
clinical practice in CKD patients.
Rather than focusing on serum ferritin levels as a predictor
of outcomes, some observational studies have examined
associations between patient outcomes and amount of iron
administered. One such study found no adverse association
between 2-year survival when the IV iron dose over 6 months
was r1000mg, but a statistically significant higher mortality
for iron doses 41000mg (adjusted hazards ratio [HR] 1.09;
95% confidence interval [CI] 1.01–1.17 for 4 1000mg to
1800mg and 1.18; 95% CI 1.09–1.27 for4 1800mg).33 How-
ever, after using multivariable models accounting for
time-varying measures of iron administration and other
parameters, there was no statistically significant association
between any level of iron administration and mortality.
Another retrospective study using time-dependent and multi-
variate adjustment for case mix found that IV iron doses up to
400mg/month were associated with lower death rates
compared to doses 4400mg/month35 (Supplementary Table
5 online).
It is the consensus of the Work Group that additional IV
iron should not routinely be administered in patients with
Figure 2 | Sensitivity and specificity of TSAT and serum ferritin
(ferritin) and their combination (TSAT þ ferritin) and bone
marrow iron (BM iron) to identify correctly a positive
erythropoietic response (Z1-g/dl [Z10-g/l] increase in Hb
[DHb]) to intravenous iron in 100 nondialysis patients with
CKD (areas under the ROCs). Reproduced with permission from
American Society of Nephrology40 from Stancu S, Barsan L,
Stanciu A et al. Can the response to iron therapy be predicted in
anemic nondialysis patients with chronic kidney disease? Clin J Am
Soc Nephrol 2010; 5: 409–416; permission conveyed through
Copyright Clearance Center; accessed http: http://
cjasn.asnjournals.org/content/5/3/409.long
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serum ferritin levels that are consistently 4500 ng/ml
(4500 mg/l). In patients with Hb below the desired level
who are receiving relatively high ESA doses, or in whom
discontinuation of ESA therapy is preferred (for instance a
CKD patient with malignancy), a therapeutic trial of
additional IV iron (i.e., a single course of up to 1000mg
over a period of several weeks which can be repeated as
needed) may be undertaken in patients with serum ferritin
levels 4500 ng/ml (4500 mg/l) after due consideration of
potential acute toxicities and long-term risks. Subsequent
treatment decisions should be based on the patient’s clinical
status, including trends in TSAT, ferritin, and Hb level, and
ESA dose and responsiveness.
Ferritin levels need to be interpreted with caution in
patients who may have an underlying inflammatory condi-
tion as they may not predict iron stores or responsiveness to
iron therapy in a manner similar to that when inflammation
is absent. In the absence of a clinically evident infectious or
inflammatory process, assessment of CRP may suggest the
presence of an occult inflammatory state that may be
associated with an elevated ferritin level and ESA-hypor-
esponsiveness (Supplementary Table 6 online).
Other iron status tests not as widely available as TSAT and
ferritin such as percentage of hypochromic red cells,
reticulocyte Hb content, zinc protoporphyrin, and soluble
transferrin receptors may be used to assess iron status, but are
less well studied.22,23
There is no evidence that a higher ferritin target of 200
ng/ml (200 mg/l) is the appropriate or inappropriate
cutoff in CKD 5HD pediatric patients. Consequently no
change has been made to the 2006 KDOQI guideline in
children with CKD and anemia, which recommended a
ferritin target greater than 100 ng/ml (100 mg/l) for CKD
5HD, as well as for CKD 5PD and CKD ND who are not on
ESA therapy.58
Iron treatment
A decision to provide an individual patient with iron therapy
should be based on an assessment that an increase in Hb level
is desirable, that is, to avoid transfusions or reduce anemia-
related symptoms, and that the potential adverse effects of
iron supplementation, either oral or IV, have been considered
and are appropriately outweighed by the expected treatment
benefit. Such supplementation could be in the form of oral or
intravenous iron. Use of intramuscular iron has largely been
abandoned. Each route has its own potential advantages and
disadvantages. Oral iron is inexpensive, readily available, and
does not require IV access, a particular concern in CKD
patients not on HD. It is also not associated with severe
adverse effects but gastrointestinal side effects are common
and may limit adherence. This, along with variable gastro-
intestinal tract absorption, limits the efficacy of oral iron. IV
iron avoids concerns about medication adherence and
efficacy in treating iron deficiency, but requires IV access
and has been associated with infrequent but severe adverse
reactions. Decisions about the preferred route of iron
supplementation should take into consideration severity of
anemia and iron deficiency, the response, tolerance and
adherence to prior oral iron administration, costs, and ease of
obtaining venous access balanced against the desire to
preserve venous access sites.
In patients with CKD ND, the available evidence supports
an efficacy advantage of IV compared with oral administra-
tion of iron although the effect is rather small, with a
weighted mean Hb difference of 0.31 g/dl (3.1 g/l).45,59–63
Whether the small Hb benefit of IV iron in CKD ND patients
is clinically meaningful or justifies the small risk of serious
adverse events and unknown long-term risks is uncertain.
The consensus of the Work Group is that a clearly defined
advantage or preference for IV compared to oral iron was not
supported by available evidence in CKD ND patients.
Therefore, in such patients, the route of iron administration
can be either IV or oral. In some patients the desire to avoid
venipuncture (and preserve IV access) may favor in some
patients, particularly those with mild iron deficiency, an
initial trial of oral iron.
Oral iron is typically prescribed to provide approximately
200mg of elemental iron daily (for instance ferrous sulfate
325mg three times daily; each pill provides 65mg elemental
iron). Smaller daily doses may be useful and better tolerated
in some patients. Although ferrous sulfate is commonly
available and inexpensive, other oral iron preparations
may also be used; there is not significant evidence to suggest
that other oral iron formulations are more effective or
associated with fewer adverse side effects than ferrous
sulfate. If the goals of iron supplementation are not met
with a 1–3 month course of oral iron, it is appropriate to
consider IV iron supplementation in a manner consistent
with the above recommendation statements and the discus-
sion that follows.
There is evidence supporting a preference for the IV
route of iron administration in CKD 5HD patients
derived from RCTs and other studies comparing IV iron
with oral iron and placebo, with and without concomitant
ESA treatment.27,32,62,64,65 In most of these studies,
IV iron administration led to a greater increase in Hb
concentration, a lower ESA dose, or both. In CKD 5HD
patients, the ready IV access and convenience of being able to
administer IV iron during HD treatments further supports
the preference for the IV route for iron administration in
these patients.
In prior CKD anemia guidelines,50 CKD 5PD patients
were considered more similar to CKD ND than CKD 5HD in
their need for and likely responsiveness to iron, as well as in
their absence of ready venous access for IV iron administra-
tion. Limited studies of iron administration in CKD
5PD patients indicate that oral iron is of limited efficacy
and that IV iron is superior to oral iron in terms of achieved
Hb level and ESA dose. Consequently, this route is preferred
in these patients, although the desire to preserve potential
future venous access sites must be considered in such
patients.66–70
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IV iron may be provided as a single large dose or as
repeated smaller doses depending on the specific IV iron
preparation used (with the highest single dose varying by
specific formulation). It is common practice to provide an
initial course of IV iron amounting to approximately
1000mg; this may be repeated if an initial dose fails to
increase Hb level and/or allow a decrease in ESA dose and if
the TSAT remains r30% and serum ferritin remains
r500 ng/ml (r500 mg/l).38
Decisions regarding continued iron therapy should take
into consideration recent patient responses to iron therapy,
iron status tests (TSAT and ferritin), Hb concentration, ESA
responsiveness and ESA dose in ESA-treated patients,
ongoing blood losses, trends in each parameter, and the
patient’s clinical status. Serum ferritin and TSAT levels
should not be measured until at least one week has elapsed
since the most recent prior IV iron dose. Consideration of
expected iron needs and evaluation for ongoing iron losses
should precede further IV iron administration. Blood loss
should be minimal in CKD ND and CKD 5PD patients, while
CKD 5HD patients have reported to lose between 1–2 gm of
iron per year related to the HD procedure and related
circumstances.71–73 Thus, an apparent ongoing need for any
iron supplementation in CKD ND and CKD 5PD patients or
for more than 1–2 gm/yr in CKD 5HD patients should
prompt assessment for a source of active blood loss. The need
to consider trends in iron status tests are highlighted by
consideration of a patient with decreasing TSAT and ferritin
levels which may signify the presence of gastrointestinal
bleeding or excessive dialysis-associated blood loss. As
another example, an increasing TSAT and ferritin level may
indicate excessive iron supplementation and a need to
decrease or discontinue iron administration. Finally, an
increase in ferritin level accompanied by a decrease in TSAT
and Hb level suggests inflammation-mediated reticuloen-
dothelial blockade.14
There are two commonly used approaches to ongoing
or maintenance IV iron treatment in CKD 5HD patients:
(1) periodic iron repletion, consisting of a series of IV iron
doses administered episodically to replenish iron stores
whenever iron status tests indicate the likelihood of iron
deficiency or decrease below specific target levels; or (2)
maintenance treatment, consisting of smaller doses adminis-
tered at regular intervals to maintain iron status tests stable
within specific limits with the intent of avoiding iron
deficiency or decline of iron test parameters below specific
levels. Limited evidence suggests that regular maintenance IV
iron administration in CKD 5HD is associated with use of
lower ESA doses and may result in lower cumulative iron
doses41,74,75 but these data are insufficient to support a
recommendation favoring any particular IV iron dosing
strategy in this patient population. By nature of the clinical
encounters with CKD 5PD patients, IV iron supplementation
is often provided at periodic (e.g., monthly) visits.
Overall, the TSAT and ferritin recommendations above are
applicable to children with CKD on ESA therapy. However,
there is no evidence that a higher ferritin target of 200 ng/ml
(200 mg/l) is the appropriate or inappropriate cutoff in
pediatric CKD HD patients. Consequently no change has
been made to the 2006 KDOQI guideline in CKD in children
with anemia, which recommended a ferritin target greater
than 100 ng/ml (100 mg/l) for CKD 5HD, as well as for CKD
5PD and CKD ND who are on ESA therapy.58
IRON STATUS EVALUATION
2.2.1: Evaluate iron status (TSAT and ferritin) at least
every 3 months during ESA therapy, including the
decision to start or continue iron therapy. (Not
Graded)
2.2.2: Test iron status (TSAT and ferritin) more frequently
when initiating or increasing ESA dose, when
there is blood loss, when monitoring response after
a course of IV iron, and in other circumstances
where iron stores may become depleted. (Not
Graded)
RATIONALE
In the absence of clinical trials that specifically inform
the optimal frequency for testing of iron status, and
consistent with prior guidelines,50 the consensus of the Work
Group is that patients who are on ESA therapy, regardless of
whether iron treatment is also being used, should have tests
of iron status at least every 3 months. Falling TSAT and/or
ferritin levels are likely to reflect ongoing blood loss or
consumption of available iron stores, and can be used to
anticipate the need for future or additional iron supplemen-
tation. In patients on oral iron treatment, iron status testing
can also be used to assess adherence with iron treatment.
Increasing TSAT and/or ferritin levels may indicate that iron
treatment is excessive and can be stopped or reduced.
Increasing ferritin levels in association with stable or
declining TSAT levels may also indicate the presence of
inflammation, infection, or other clinical situations inducing
acute phase reactants during which time the appropriate-
ness of continued iron administration may need to be
reassessed.14
In some circumstances, more frequent iron status testing
may be appropriate, including following initiation of ESA or
iron therapy or when the ESA dose or dose frequency is
increased. Iron status testing is also important in the
assessment of patients who become less responsive to ESA
treatment.
Despite the absence of specific data in the pediatric CKD
population, this recommendation is considered applicable to
children since there are no reasons to suggest a different
recommendation. Since the 2006 KDOQI guideline for
anemia in pediatric CKD,58 no new evidence regarding iron
therapy for children with CKD has been published. The
suggestion for oral iron supplementation in children is
2–6mg/kg/day of elemental iron in 2–3 divided doses.76,77 An
RCTof 35 iron replete pediatric CKD 5HD patients evaluated
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their response to either weekly IV iron dextran dosed by
weight or oral iron 6mg/kg/day. Only the IV iron dextran
produced a significant increase in the serum ferritin levels
and showed a significant decrease in ESA dose required to
maintain target Hb levels.78 An international multicenter
double-blind RCT investigated the safety and efficacy of two
dosing regimens (1.5mg/kg or 3mg/kg) of ferric gluconate in
iron-deficient pediatric hemodialysis patients receiving con-
comitant ESA therapy. Efficacy and safety profiles were
comparable, with no unexpected adverse events with either
dose.79 Based on this trial, the recommendation for initial
ferric gluconate therapy is 1.5mg/kg for eight doses for iron-
deficient pediatric CKD 5HD patients and 1mg/kg per
week for iron-replete pediatric CKD 5HD patients, with
subsequent dose adjustments made according to TSAT
and/or ferritin levels.79,80 Iron sucrose has also been used in
children with CKD81 but, as of yet, no RCTs have been
published in this population. Although it is not uncommon
that pediatric CKD 5PD and CKD ND patients either do not
respond to or tolerate oral iron therapy, the need for IV access
for parenteral iron therapy often limits its utilization in
children.
CAUTIONS REGARDING IRON THERAPY
2.3: When the initial dose of IV iron dextran is adminis-
tered, we recommend (1B) and when the initial dose
of IV non-dextran iron is administered, we suggest
(2C) that patients be monitored for 60minutes after
the infusion, and that resuscitative facilities (including
medications) and personnel trained to evaluate and
treat serious adverse reactions be available.
RATIONALE
Any form of IV iron may be associated with potentially
severe acute reactions.82–91 The symptoms of most concern
are hypotension and dyspnea, which in the worst cases may
be catastrophic with features of anaphylaxis. The cause
of reactions has not been fully characterized, but may
involve immune mechanisms and/or release of free,
reactive iron into the circulation with induction of oxidative
stress. The mechanisms of acute reactions may differ for
different iron preparations. Certain iron dextrans in parti-
cular have been associated with reactions characteristic of
anaphylaxis. The rate of such reactions is estimated to occur
in 0.6–0.7% of patients treated. The serious adverse effect
event rate may be lower with low molecular weight iron
dextran compared to high molecular weight iron dex-
tran.92–96
With non-dextran IV iron drugs, it is believed that
anaphylactoid and other severe and potentially life-threaten-
ing reactions are less common, but this has not been well
substantiated. Serious reactions including profound hypo-
tension do occur, even if uncommonly, with all non-dextran
IV iron preparations. Because all forms of IV iron drugs can
be associated with serious immediate reactions, they should
be used with vigilance. Since the rate of such reactions
may be greater for iron dextran drugs we recommend
that resuscitative medications and personnel trained to
evaluate and treat serious adverse reactions be available
when the initial dose of IV iron dextran is administered.
The data to support such a recommendation for the initial
dose of non-iron dextran compounds is not as strong. In the
US, the Food and Drug Administration (FDA)-mandated
labeling for ferumoxytol specifies that patients be observed
for 60minutes after administration. This may be reasonable
advice for all IV iron drugs, including other new iron
preparations such ferric carboxymaltose and iron isomalto-
side. For each IV iron preparation prescribing physicians
should be familiar with the drug’s safety and toxicity profile
and the product labeling warnings and recommendations
for administration, as well as patient monitoring during and
after treatment.
Iron during infection
2.4: Avoid administering IV iron to patients with active
systemic infections. (Not Graded)
RATIONALE
Iron is essential for the growth and proliferation of most
pathogens including many bacteria, viruses, fungi, parasites
and helminthes, and also exerts subtle effects on immune
function and host responses towards microbes.97 There is
theoretical and experimental evidence to suggest that iron
administration may worsen an existing infection but clinical
evidence is lacking. In animal models, iron overload results in
an impaired control of infections, specifically with intracel-
lular bacteria or fungi.98–101 In humans, tissue iron overload
has been considered as a risk factor for the acquisition of
certain infections and for an unfavorable clinical course of
the infection. Data in CKD patients are conflicting.102–104
Since current evidence cannot provide a clear answer as to
whether specific CKD patient groups are at increased risk for
infection, or of having a poorer outcome with infection when
anemia is treated with IV iron, the Work Group suggests that
IV iron not be administered when patients have an active
systemic infection. Clinical judgment is necessary in each
individual patient to assess whether there is an immediate
need for IV iron (as opposed to delaying treatment until
resolution of an infection), likelihood of achieving benefit
from a dose of IV iron in the setting of an active infection,
and the severity of an infection.
RESEARCH RECOMMENDATIONS
Much regarding the testing of iron status and use of iron
supplementation, particularly IV, in CKD patients of all
stages remains unknown. There is a serious lack of large,
prospective clinical trials with assessment of clinically mean-
ingful outcomes and toxicities; rather, most have been small,
short-term studies focusing primarily on surrogate outcomes
such as increase in Hb level and reduction in ESA dose. Some
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important questions that should be addressed in future
studies might include:
K What is the comparative risk-benefit balance of various
treatment strategies that include differing ratios of ESA
dosing and iron supplementation to achieve a particular
Hb level?
K Is there a role, and if so under what circumstances, for
anemia management in CKD patients with iron alone,
without ESA treatment (or with only ESA ‘rescue
therapy’ for particularly low Hb levels)?
K Is there important long-term toxicity of IV iron
supplementation and if so, under what circumstances
and in what CKD patient groups?
K Is IV iron administration, with or without concomitant
ESA dose increases, safe and of clinical benefit, in patients
with ferritin levels 4500–800 ng/ml (4500–800 mg/l)?
K What are the best laboratory tests to guide decisions
regarding initiation, ongoing treatment, and discontinua-
tion of iron supplementation?
K Is current iron and anemia management in pediatric
CKD patients appropriate?
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